Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate
Executive Summary
Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.
You may also be interested in...
Video: Interview With Baiju Shah Of BioMotiv
In an interview at the recent BioPharm America conference, Shah explains the role that BioMotiv, a self-described accelerator, plays in advancing academic research into private-sector biopharma companies.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.